Shares spike on no news, but that happens in the land of small-cap biotechs.
Looking for income in today's yield-starved world? Here's why these three stocks fit the bill.
Traders flee after the company announces that it is merging with a privately held drugmaker.
Investing is a potent way to grow wealth, but picking individual stocks isn't for everyone. If you're seeking other options, consider the Schwab U.S. Small-Cap ETF, SPDR S&P 500 ETF, and Vanguard FTSE All-World ex-US ETF.
Shares soar after the company notches an important regulatory win.
Let's put the two retail pharma giants to the test to determine which is the better bet for new money today.
Here's why these two businesses are wonderful buy-and-hold candidates.
Looking for a few rock-solid businesses to buy? Here are three gems that you should consider.
Looking for a few stocks that offer big-time profit potential? Take a look at these three businesses.
Looking for a few timely stock picks from the pros? Consider giving these three companies a closer look.
Bullish commentary from an analyst allowed Exact Sciences' huge rally to continue.
Management poured cold water on its financial projections for 2017, causes shares to take a step back.
Positive results from an important phase 3 clinical trial fueled optimism about the biotech.
The release of phase 3 trial results that failed to impress led to a sinking share price.
Looking for a few great stocks to buy this month? Here are five top opportunities for you to consider.
Searching for income? You can follow in the masters' footsteps by checking out these high-yield stocks.
Looking for a big dividend payment in today's pricey market? Here are three stocks that show why you should look beyond the U.S. border.
Traders cheer after management provided investors with a series of positive updates.
Results from a phase 1 study failed to impress investors.
Big pharma companies have thrown hundreds of millions of dollars at this small biotech. Should retail investors follow suit?